Please note that this meeting will take place as an in-person event in Los Angeles and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

[R] – Remote Presentation

Thursday, March 5

• Welcome and Keynote Lectures

Friday, March 6

• Plenary Session 1: RAS Biochemistry, Structure, and Mutations
• Plenary Session 2: Effector Signaling
• Plenary Session 3: Colorectal Cancer: Therapeutic Challenges and Opportunities
• Plenary Session 4: RAS omics and Early Detection Advances

Saturday, March 7

• Keynote Lecture
• Plenary Session 5: RAS Clinical Trials and New Therapies
• Plenary Session 6: Combinations
• Plenary Session 7: Immunobiology and Immunotherapies for RAS Malignancies
• Special Session from the NCI RAS Initiative

SUNday, March 8

• Plenary Session 8: Resistance Mechanisms
• Plenary Session 9: Targeting NRAS, HRAS, and Rare KRAS Subtypes

REGISTRATION

3-7 p.m. | Diamond 1-4 Foyer 

WELCOME AND Keynote lectures

6-7:30 p.m. | Diamond 5 

Session Chair: Kevan M. Shokat, University of California, San Francisco, California

• 6 p.m. | Opening Keynote
  Drugging RAS: What a long, strange trip it’s been  
  Channing Der, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
• 6:45 p.m. | Rising Star Keynote
  Response and resistance to RAS blockade in solid tumors and beyond
  Sandra Misale, Johns Hopkins University, Baltimore, Maryland

Opening Reception

7:30-9 p.m. | Diamond 1-3

CONTINENTAL BREAKFAST

7-8 a.m. | Diamond 1-3

NETWORKING ROUNDTABLES

7-8 a.m. | Diamond 1-3

Choosing a Career Path: Academia vs Industry Mallika Singh	How to Get a Paper Published Andrew Aguirre
Balancing Clinical and Research responsibilities David S. Hong	Collaborating with industry Channing Der
Starting your lab Chiara Ambrogio

Plenary Session 1: RAS Biochemistry, Structure, and Mutations

8-10 a.m. | Diamond 5 

Session Chair: Jessie Villanueva, The Wistar Institute, Philadelphia, Pennsylvania

• 8:05 a.m. | Piro Lito, Memorial Sloan Kettering Cancer Center, New York, New York
• 8:35 a.m. | Differential biology of KRAS splice variants
  Mark Philips, New York University Perlmutter Cancer Center, New York, New York
• 9:05 a.m. | Identification of a RAS-GTP threshold for malignant transformation* 
  Sophie Krahnke, Frederick National Laboratory, Frederick, Maryland
• 9:15 a.m. | Targeting S6K2 overcomes resistance to RAS inhibition in NRAS-mutant melanoma*
  Jessie Villanueva
• 9:25 a.m. | Discussion

BREAK

10-10:15 a.m. | Diamond 1-4 Foyer

Plenary Session 2: Effector Signaling

10:15 a.m.-12:15 p.m. | Diamond 5 

Session Chair: Dieter Saur, German Cancer Research Center and Technical University of Munich, Munich, Germany

• 10:20 a.m. | Spatiotemporal determinants of KRAS effector signaling in PDAC: From subclonal evolution to stromal–immune niches
  Dieter Saur
• 10:50 a.m. | Targeting the SHOC2-RAS interaction in RAS-mutant cancers
  Zachary Hauseman, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 
• 11:20 a.m. | MEK1/2 degraders uncover kinase-independent role of MEK1/2 in CRAF stabilization and maturation*
  James Duncan, Fox Chase Cancer Center, Philadelphia, Pennsylvania
• 11:30 a.m. | Dissecting the critical ERK functions that support KRAS-driven pancreatic cancer*
  Jennifer Klomp, Michigan State University, Grand Rapids, Michigan
• 11:40 a.m. | Discussion

Lunch on Own

12:15-2:15 p.m.

Plenary Session 3: Colorectal Cancer: Therapeutic Challenges and Opportunities

2:15-4:15 p.m. | Diamond 5 

Session Chair: Ryan Corcoran, Massachusetts General Hospital, Boston, Massachusetts

• 2:20 p.m. | Combination strategies to overcome adaptive and acquired resistance to RAS targeted therapy in colorectal cancer 
  Rona Yaeger, Memorial Sloan Kettering Cancer Center, New York, New York
• 2:50 p.m | Rethinking RAS targeting in colorectal cancer: Beyond G12C through novel mechanisms and combinations
  Ignacio Garrido-Laguna, Moffitt Cancer Center, Tampa, Florida
  Ryan Corcoran
• 3:20 p.m. | Therapeutic strategies to increase the efficacy of KRAS inhibition in colorectal cancer
  Ryan Corcoran
• 3:50 p.m. | Discussion

Presentation of Awards to the Conference Cochairs

4:25-4:30 p.m. | Diamond 5 

Presented by: Ryan Corcoran, Massachusetts General Hospital, Boston, Massachusetts

break

4:30-4:45 p.m. | Diamond 1-4 Foyer

Plenary session 4: RAS omics and Early Detection Advances

4:45-6:30 p.m. | Diamond 5 

Session Chair: Marina Pasca di Magliano, University of Michigan, Ann Arbor, Michigan

• 4:50 p.m. | 3D genomic analysis reveals frequent KRAS Mutations in multifocal pancreatic precancer
  Laura Wood, Johns Hopkins University, Baltimore, Maryland
• 5:20 p.m. | Oncogenic Kras as a driver of the pancreatic cancer microenvironment
  Marina Pasca di Magliano
• 5:50 p.m. | KRAS amplification as de novo oncogenic alteration and therapeutic target in human cancers*
  Mark Awad, Memorial Sloan Kettering Cancer Center, New York, New York
• 6 p.m. | Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity*
  Jason Kwon, Dana-Farber Cancer Institute, Boston, Massachusetts
• 6:10 p.m. | Discussion

Poster Session A and Reception

6:45-8:45 p.m. | Diamond 4

CONTINENTAL BREAKFAST

7-8 a.m. | Diamond 1-3

Networking Roundtables           

7-8 a.m. | Diamond 1-3

Choosing a Career Path: Academia vs Industry Zachary Hauseman	How to Get a Paper Published Mark Philips
Balancing Clinical and Research responsibilities Eileen O’Reilly	Collaborating with industry Mariano Barbacid Julian Downward
How to write a grant Kevin Haigis

Keynote Lecture

8-8:45 a.m. | Diamond 5 

Session Chair: Channing J. Der, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

• 8 a.m. | Targeting the oncogenic state of RAS: Lessons from tri-complex inhibitors
  Mallika Singh, Revolution Medicines, Redwood City, California
• 8:35 a.m. | Discussion

Plenary Session 5: RAS Clinical Trials and New Therapies

8:45-10:45 a.m. | Diamond 5 

Session Chair: David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, Texas

• 8:50 a.m. | Ferdinandos Skoulidis, UT MD Anderson Cancer Center, Houston, Texas
• 9:20 a.m. | Pancreas cancer: Genomics, RAS therapeutics, and clinical landscape
  Eileen O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York
• 9:50 a.m. | Anti-tumor efficacy of the selective oral KRAS G12D dual ON/OFF inhibitor VS-7375 as a single agent and in combination with targeted agents*
  Jonathan Pachter, Verastem Oncology, Needham, Massachusetts
• 10 a.m. | Preclinical activity of an orally bioavailable PROTAC pan-KRAS degrader versus inhibitors in mutant KRAS models*
  Andrea Lopez-Arroyo, Arvinas Operations Inc, New Haven, Connecticut
• 10:10 a.m. | Discussion

Break

10:45-11 a.m. | Diamond 1-4 Foyer

Plenary Session 6: Combinations

11 a.m.-1:30 p.m. | Diamond 5 

Session Chair: Karen Cichowski, Brigham and Women’s Hospital, Boston, Massachusetts

• 11:05 a.m. | Targeting KRAS driven pancreatic cancer: Combination therapies   
  Mariano Barbacid, Spanish National Cancer Research Center (CNIO), Madrid, Spain 
• 11:35 a.m. | Developing combinatorial therapies for RAS driven cancers
  Karen Cichowski
• 12:05 p.m. | Targeting KRAS in pancreatic cancer
  David Tuveson, Cold Spring Harbor Laboratory, New York, New York
• 12:35 p.m. | The RAS(ON) multi-selective inhibitor, daraxonrasib (RMC-6236), induces Receptor Tyrosine Kinase (RTK) cell surface expression on pancreatic cancer cells, providing rationale for combinations with RTK targeting agents* 
  Ida Aronchik, Revolution Medicines, Redwood City, California
• 12:45 p.m. | ERK hyperactivation-induced lethality as a therapeutic strategy in RAS-driven tumors* 
  Alexa C. Cannon, Novartis Biomedical Research, Cambridge, Massachusetts
• 12:55 p.m. | Discussion

Lunch on Own

1:30-3:15 p.m.

Plenary Session 7: Immunobiology and Immunotherapies for RAS Malignancies

3:15-5:45 p.m. | Diamond 5 

Session Chair: Ron DePinho, UT MD Anderson Cancer Center, Houston, Texas

• 3:20 p.m. | Engineering T cells for effectively targeting KRAS-driven tumors 
  Philip Greenberg, Fred Hutchinson Cancer Center, Seattle, Washington
• 3:50 p.m. | Mutant KRAS-targeted vaccines for cancer treatment and interception
  Elizabeth Jaffee, Johns Hopkins University School of Medicine, Baltimore, Maryland
• 4:20 p.m. | The state of KRAS resistance 
  Ron DePinho
• 4:50 p.m. | KRAS amplification creates a targetable pMHC antigen for T cell engager therapy to overcome KRAS inhibitor resistance*
  Lauren Stopfer, Aethon Therapeutics, New York, New York
• 5 p.m. | Kras G12C and G12D driven lung cancers differ in oncogenic potency, immunogenicity, and relapse following Kras inhibition* 
  Esra A. Akbay, University of Texas Southwestern Medical Center, Dallas, Texas
• 5:10 p.m | Discussion

Break

5:45-6 p.m. | Diamond 1-4 Foyer

Special Session from the u.s. national cancer institute ras initiative

6-7:30 p.m. | Diamond 5 

Session Chair: Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, and Frederick National Laboratory for Cancer Research, Frederick, Maryland

• 6:10 p.m. | Mechanistic insights on RAF activation through AI-driven multiscale simulation coupled with experimental validation
  Dwight V. Nissley, Frederick National Laboratory for Cancer Research, Frederick, Maryland
• 6:30 p.m. | Allosteric regulation of SOS by RRAS2
  Andrew Stephen, Frederick National Laboratory for Cancer Research, Frederick, Maryland
• 6:50 p.m. | Dhirendra Simanshu, Frederick National Laboratory for Cancer Research, Frederick, Maryland
• 7:10 p.m. | Discussion

Poster Session B and Reception

7:30-9:30 p.m. | Diamond 4

Continental Breakfast and Networking Roundtables

7-8 a.m.

Plenary Session 8: Resistance Mechanisms

8-10 a.m. | Diamond 5 

Session Chair: Chiara Ambrogio, Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy 

• 8:05 a.m. | Signaling plasticity in pre-clinical models of resistance to KRAS inhibitors
  Chiara Ambrogio
• 8:35 a.m. | Boosting the immune system to counter resistance to KRAS inhibitory drugs in lung cancer 
  Julian Downward, The Francis Crick Institute, London, United Kingdom
• 9:05 a.m. | Dynamic kinome reprogramming and metabolic rewiring drive adaptive resistance to RAS inhibition in pancreatic cancer* 
  Clint A. Stalnecker, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
• 9:15 a.m. | A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer*
  Goutham Narla, The University of Michigan, Ann Arbor, Michigan
• 9:25 a.m. | Discussion

Break

10-10:15 a.m. | Diamond 1-4 Foyer

Plenary Session 9: Targeting NRAS, HRAS, and Rare KRAS Subtypes

10:15 a.m.-12:45 p.m. | Diamond 5 

Session Chair: Martin McMahon, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

• 10:20 a.m. | Targeting the palmitoylation cycle in NRAS-mutant cancers 
  Kevin Shannon, University of California, San Francisco, San Francisco, California
• 10:50 a.m. | Factors regulating permissively of organs to oncogenic RAS 
  Kevin Haigis, Dana-Farber Cancer Institute, Boston, Massachusetts
• 11:20 a.m. | Drivers of sensitivity or resistance to RAS(ON) multi-selective inhibitors in NRAS-mutated melanoma 
  Martin McMahon
• 11:50 a.m. | Silent KRAS mutations confer altered sensitivity to targeted KRAS inhibition*
  Andrew  M. Waters, University of Cincinnati, Cincinnati, Ohio
• 12 p.m. | De novo design of Ras isoform selective binders*
  Jason Z.  Zhang, University of California Los Angeles, Los Angeles, California
• 12:10 p.m. | Discussion

Closing Remarks

12:45 p.m. | Diamond 5 

• Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts